Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.

Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H, Yang G.

J Clin Endocrinol Metab. 2013 Jan;98(1):290-8. doi: 10.1210/jc.2012-2466. Epub 2012 Nov 26.

PMID:
23185036
2.
3.

Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.

Li M, Yang M, Zhou X, Fang X, Hu W, Zhu W, Wang C, Liu D, Li S, Liu H, Yang G, Li L.

J Clin Endocrinol Metab. 2015 Apr;100(4):1485-93. doi: 10.1210/jc.2014-2544. Epub 2015 Feb 12. Erratum in: J Clin Endocrinol Metab. 2015 Aug;100(8):3219.

PMID:
25675380
4.

Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance.

Hu Z, Deng H, Qu H.

Diabetes Res Clin Pract. 2013 Mar;99(3):391-5. doi: 10.1016/j.diabres.2012.11.026. Epub 2013 Jan 3.

PMID:
23290274
5.

Circulating SFRP5 levels are elevated in drug-naïve recently diagnosed type 2 diabetic patients as compared with prediabetic subjects and controls.

Canivell S, Rebuffat S, Ruano EG, Kostov B, Sisó-Almirall A, Novials A, Ceriello A, Gomis R.

Diabetes Metab Res Rev. 2015 Feb;31(2):212-9. doi: 10.1002/dmrr.2599. Epub 2014 Oct 21.

PMID:
25139699
6.

Roles of circulating WNT-signaling proteins and WNT-inhibitors in human adiposity, insulin resistance, insulin secretion, and inflammation.

Almario RU, Karakas SE.

Horm Metab Res. 2015 Feb;47(2):152-7. doi: 10.1055/s-0034-1384521. Epub 2014 Aug 4.

PMID:
25089371
7.

Circulating secreted frizzled-related protein 5 (Sfrp5) and wingless-type MMTV integration site family member 5a (Wnt5a) levels in patients with type 2 diabetes mellitus.

Lu YC, Wang CP, Hsu CC, Chiu CA, Yu TH, Hung WC, Lu LF, Chung FM, Tsai IT, Lin HC, Lee YJ.

Diabetes Metab Res Rev. 2013 Oct;29(7):551-6. doi: 10.1002/dmrr.2426.

PMID:
23653377
8.

SFRP5 correlates with obesity and metabolic syndrome and increases after weight loss in children.

Tan X, Wang X, Chu H, Liu H, Yi X, Xiao Y.

Clin Endocrinol (Oxf). 2014 Sep;81(3):363-9. doi: 10.1111/cen.12361. Epub 2013 Dec 12.

PMID:
24330025
9.

Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.

Díaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E.

Diabetes Res Clin Pract. 2014 Apr;104(1):92-6. doi: 10.1016/j.diabres.2014.01.019. Epub 2014 Jan 25.

PMID:
24530118
10.
11.

Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.

Svendsen PF, Nilas L, Madsbad S, Holst JJ.

Metabolism. 2009 May;58(5):586-93. doi: 10.1016/j.metabol.2008.11.009.

PMID:
19375579
12.

Balanced duo of anti-inflammatory SFRP5 and proinflammatory WNT5A in children.

Prats-Puig A, Soriano-Rodríguez P, Carreras-Badosa G, Riera-Pérez E, Ros-Miquel M, Gomila-Borja A, de Zegher F, Ibáñez L, Bassols J, López-Bermejo A.

Pediatr Res. 2014 Jun;75(6):793-7. doi: 10.1038/pr.2014.29. Epub 2014 Mar 6.

PMID:
24603290
13.

Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.

Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Macut D, Panidis D.

Hum Reprod. 2013 Mar;28(3):785-93. doi: 10.1093/humrep/des456. Epub 2013 Jan 12.

14.

Differences in insulin sensitivity, pancreatic beta cell function and circulating adiponectin across glucose tolerance status in Thai obese and non-obese women.

Chailurkit LO, Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B.

Endocrine. 2008 Feb;33(1):84-9. doi: 10.1007/s12020-008-9057-y. Epub 2008 Apr 4.

PMID:
18389389
15.

Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D.

Diabetes Care. 2009 Aug;32(8):1542-6. doi: 10.2337/dc09-0684. Epub 2009 Jun 1.

16.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

17.

Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease.

Miyoshi T, Doi M, Usui S, Iwamoto M, Kajiya M, Takeda K, Nosaka K, Nakayama R, Okawa K, Takagi W, Nakamura K, Hirohata S, Ito H.

Atherosclerosis. 2014 Apr;233(2):454-9. doi: 10.1016/j.atherosclerosis.2014.01.019. Epub 2014 Jan 22.

PMID:
24530778
18.

Wnt5a: a potential factor linking psoriasis to metabolic complications.

Gerdes S, Laudes M, Neumann K, Baurecht H, Mrowietz U.

Exp Dermatol. 2014 Jun;23(6):438-40. doi: 10.1111/exd.12413.

PMID:
24750404
19.

Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.

Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR.

Metabolism. 2013 Nov;62(11):1587-96. doi: 10.1016/j.metabol.2013.07.004. Epub 2013 Aug 17.

PMID:
23958241
20.

Sfrp5 correlates with insulin resistance and oxidative stress.

Carstensen M, Herder C, Kempf K, Erlund I, Martin S, Koenig W, Sundvall J, Bidel S, Kuha S, Roden M, Tuomilehto J.

Eur J Clin Invest. 2013 Apr;43(4):350-7. doi: 10.1111/eci.12052. Epub 2013 Feb 10.

PMID:
23398169
Items per page

Supplemental Content

Write to the Help Desk